Crossmark

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

Crossref DOI link: https://doi.org/10.1038/nature21428

Published Online: 2017-02-02

Published Print: 2017-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pardi, Norbert

Hogan, Michael J.

Pelc, Rebecca S.

Muramatsu, Hiromi

Andersen, Hanne

DeMaso, Christina R.

Dowd, Kimberly A.

Sutherland, Laura L.

Scearce, Richard M.

Parks, Robert

Wagner, Wendeline

Granados, Alex

Greenhouse, Jack

Walker, Michelle

Willis, Elinor

Yu, Jae-Sung

McGee, Charles E.

Sempowski, Gregory D.

Mui, Barbara L.

Tam, Ying K.

Huang, Yan-Jang

Vanlandingham, Dana

Holmes, Veronica M.

Balachandran, Harikrishnan

Sahu, Sujata

Lifton, Michelle

Higgs, Stephen

Hensley, Scott E.

Madden, Thomas D.

Hope, Michael J.

Karikó, Katalin

Santra, Sampa

Graham, Barney S.

Lewis, Mark G.

Pierson, Theodore C.

Haynes, Barton F.

Weissman, Drew
License Information

Text and Data Mining valid from 2017-02-02
More Information

Article History

Received: 14 October 2016

Accepted: 27 January 2017

First Online: 2 February 2017

Competing interests

: N.P., M.J.Hog., K.K. and D.W. are named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and vaccines. We have disclosed those interests fully to the University of Pennsylvania, and have an approved plan in place for managing any potential conflicts arising from licensing of our patents.